Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Via $950M Semma takeout, Vertex moves into diabetes and cell therapy

September 3, 2019 11:08 PM UTC

As Vertex continues to add new therapeutic areas and modalities to its portfolio, the company will pay $950 million in cash to acquire Semma and its stem cell-derived islet program. The acquisition marks Vertex's entry into diabetes and cell therapy.

Semma Therapeutics Inc. (Cambridge, Mass.) President and CEO Bastiano Sanna will serve as president of the subsidiary...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article